Background Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity eff ects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defi ned high-risk blastemal subtype was excluded from randomisation.
Introduction
Wilms' tumour (or nephroblastoma) is an embryonal kidney cancer that aff ects about 1 in 10 000 children, with 90% of cases occurring before the age of 7 years. 1 Treatment of localised, non-anaplastic Wilms' tumour, which accounts for nearly three-quarters of all cases, is highly successful, with a cure rate of almost 90%. [2] [3] [4] [5] Treatment consists of nephrectomy and chemotherapy, together with radiotherapy when the tumour is classifi ed Overall, 33-40% of all patients with unilateral, localised, non-anaplastic Wilms' tumour receive doxorubicin. 3, 5, 6 In the setting of such a highly curable childhood cancer, the reduction of potential harm from irreversible side-eff ects of treatment is of paramount importance to improve overall outcomes. [7] [8] [9] Survival from Wilms' tumour has been increasing over the past 40 years, while, paradoxically, the overall duration and intensity of treatment has been decreasing for most patients. 2, 4 This fi nding suggests that further treatment reductions could be possible for many patients.
The potential for doxorubicin to cause clinically signifi cant cardiac disease after treatment for childhood cancers has long been recognised; in some patients this cardiac disease can fi rst manifest itself more than 20 years after treatment. 10, 11 Although the risk of cardiotoxicity is related to the total cumulative dose of doxorubicin, there is probably no completely safe dosing schedule for doxorubicin, 11, 12 especially in very young patients who are typically aff ected by Wilms' tumour (median age at diagnosis 3-4 years). In the SIOP WT 2001 trial, we therefore investigated the outcome of complete removal of doxorubicin rather than a dose reduction in the relevant regimens.
The SIOP approach of neoadjuvant treatment of Wilms' tumour provides a unique opportunity to assess the in-vivo histological response of each child's tumour. Tumours are subtyped according to the proportion of necrosis and the cellular composition of the residual viable tumour. 13 Results from a retrospective analysis of the SIOP 9 and 93-01 trials 14, 15 showed that patients with blastemal-type Wilms' tumour-of which a high proportion of any surviving viable tumour after preoperative chemotherapy consists of undiff erentiated tumour cells-have a signifi cantly worse chance of event-free survival compared with patients with other subtypes of histologically determined intermediate-risk, non-anaplastic Wilms' tumour. Therefore, we classifi ed the blastemal subtype as high-risk histology, and we excluded patients with this subtype, and the diff use anaplastic subtype, from the randomised trial. 16 We aimed to assess whether doxorubicin could be safely removed from the treatment of intermediate-risk (as determined by histology), stage II-III Wilms' tumours after preoperative chemotherapy.
Methods

Study design and participants
We did an international, multicentre, unmasked, randomised, non-inferiority trial in 251 hospitals in 26 countries (appendix). A description of the trial protocol is available online. National and local regulatory and ethical approvals were obtained according to national regulations.
We recruited patients aged between 6 months and 18 years at diagnosis of a primary intrarenal tumour for randomisation of their postoperative chemotherapy.
Patients had to have received preoperative chemotherapy of 4 weeks of vincristine and actinomycin D as per protocol, and have a stage II-III intermediate-risk (as determined by histology) Wilms' tumour when assessed at delayed nephrectomy by the institutional pathologist. 16 We excluded patients with high-risk blastemal or diff use anaplastic subtypes, or evidence of metastases, and patients who had been given an immediate nephrectomy or who had not received protocol-defi ned preoperative chemotherapy, or whose legal guardians did not consent to the randomisation. Rapid central review of tumour stage and histological subtype was encouraged and available in all participating countries but was not mandated before randomisation.
The parents or legal guardians of all patients gave written informed consent at diagnosis for registration in the study, and after nephrectomy for the randomisation, when details about the tumour stage and histological risk group were available from the institutional pathologist.
Randomisation and masking
Patients' eligibility for randomisation after nephrectomy was assessed according to the local institutional pathologist's decision about tumour stage and histological risk group, and this information was submitted on a randomisation request form. We randomly assigned patients (1:1) to receive chemotherapy either with or without doxorubicin via a central computer system over the internet (ALEA, Netherlands Cancer Institute, Amsterdam, Netherlands) by a minimisation technique, stratifi ed by trial offi ce (Brazil, France, Germany, UK, and the SIOP-Amsterdam offi ce for all other countries) and pathological stage (II or III). All patients, treating clinicians, and those assessing outcomes and analysing the data were unmasked to treatment allocation.
Procedures
We used the revised SIOP tumour staging system and histological risk classifi cation (appendix) to classify tumours. 13 A percutaneous cutting needle biopsy (18 gauge) was allowed without aff ecting tumour stage. This biopsy was done routinely to confi rm histological abnormalities before starting chemotherapy only in patients treated in the UK and Ireland, according to national practice. 17 All other countries continued the well established SIOP approach of starting preoperative chemotherapy on the basis of clinical and imaging characteristics consistent with a diagnosis of Wilms' tumour, combined with measuring urinary catecholamines to exclude neuroblastoma, and reserving biopsy for cases with diagnostic dilemma. 2, 18, 19 Three-dimensional tumour volume was recorded at diagnosis and after completion of preoperative chemotherapy, according to whichever imaging method had been applied (ultrasonography, CT scan, or MRI scan). The calculated volume showed close correlation between methods (appendix). In Germany, children
See Online for appendix For trial profi le see http://www. cancerresearchuk.org/about-cancer/ fi nd-a-clinical-trial/a-trial-lookingat-treatment-for-children-andyoung-people-with-kidney-cancerincluding-wilms-tumour whose tumour volume after preoperative chemotherapy was larger than 500 mL were classifi ed as high risk and excluded from random assignment unless they had stromal or epithelial-type Wilms' tumours-subtypes that do not shrink but do have a good prognosis. 3, 20 We gave all patients the same preoperative chemotherapy of vincristine 1·5 mg/m² intravenously every week combined with actinomycin D 45 μg/kg intravenously every 2 weeks for 4 weeks, followed by unilateral nephrectomy, for which lymph node sampling was recommended but not mandatory. Randomly assigned patients received postoperative chemotherapy for 27 weeks. The treatment including doxorubicin consisted of vincristine 1·5 mg/m² (maximum dose 2 mg) intravenous bolus each week for weeks 1-8, then at weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26 , and 27, combined with actinomycin D 45 μg/kg (maximum dose 2 mg) intravenous bolus every 3 weeks from week 2, and fi ve doses of doxorubicin 50 mg/m² in 4-6 h infusions (total dose 250 mg/m²) given once every 6 weeks from week 2. The treatment excluding doxorubicin omitted doxorubicin entirely and consisted of the identical backbone of vincristine and actinomycin D only (with the same doses and timing). We reduced the dose for all drugs in patients who weighed less than 12 kg (two-thirds of the standard dose). We recommended that children with stage III Wilms' tumour receive fl ank radiotherapy (14·4 Gy) with a 10 Gy boost to locoregional lymph nodes with microscopic tumour involvement or any sites of macroscopic residual tumour, or whole abdominal radiotherapy (21 Gy) if gross tumour rupture had occurred. We modifi ed chemotherapy scheduling accordingly to avoid concurrent radiotherapy with doxorubicin or actinomycin D.
We ascertained patient demographic characteristics, tumour characteristics and response, treatments given, adverse events, and outcomes from standard case report forms completed at registration, the end of preoperative chemotherapy, after nephrectomy, at the end of treatment, and annually thereafter or at the time of any event. These were submitted to one of fi ve national trial offi ces in Brazil, France, Germany, the Netherlands, and the UK. The Netherlands trial offi ce (SIOP-NL) registered patients from all other participating countries and held the master trial database that received 6 monthly data transfers from the other trial offi ces. Spain started a national trial offi ce in March, 2007, but was not deemed as a separate offi ce for stratifi cation of randomisation because of the few cases randomised in the time period. We assessed safety and adverse events through specifi c sections in the case report forms.
Outcomes
The primary endpoint of the trial was to test the non-inferiority of 2 year event-free survival between treatment including doxorubicin versus treatment excluding doxorubicin. Secondary outcomes were 5 year event-free survival and 5 year overall survival.
Both treatment regimens are well tolerated, 15 hence our assessment of safety and adverse events focused on systematic monitoring of hepatic toxicity and cardiotoxicity, which are infrequent but sometimes serious side-eff ects of actinomycin D (hepatic toxic eff ects) and doxorubicin (cardiotoxic eff ects). 
Statistical analysis
We assumed a 2 year event-free survival of 86%, with a non-inferiority margin of 10%, 5% type I error, and 80% power, and estimated that at least 350 patients would need to be included in our study. 21 Our assumption of 86% event-free survival was based on the data from the SIOP 93-01 study, 3 in which two-thirds of potentially eligible patients had stage II (2 year event-free survival 88%) and a third had stage III (2 year event-free survival 83%) Wilms' tumour, and in which blastemal-type Wilms' tumour would have been included within intermediate-risk histology because its recognition was not required by the local pathologist. However, since this subtype includes less than 9% of all localised Wilms' tumours, its removal would be unlikely to have a major eff ect on the predicted numbers for the calculation of sample size. We estimated that patient accrual would take 7 years, and another 2 years of follow-up would be needed to analyse the data at full power. The trial reached its target sample size early (Nov 6, 2006) . Hence, the trial management group, in conjunction with the Independent Data Monitoring Committee review of the Feb 17, 2007, interim analysis, agreed to increase the sample size to 550 randomly assigned patients to provide about 104 events for an increased power of 90% and a reduction in the type I error to 0·025 (one sided) to improve the reliability of the overall results and to allow separate analysis of stage II and III tumours.
The intention-to-treat analyses included all randomly assigned patients. The primary endpoint of 2 year event-free survival was fi rst analysed when the last randomly assigned patient had a minimum of 2 years of follow-up. Event-free survival was calculated from the date of randomisation to the date of recurrence or death, whichever happened fi rst. Patients alive and without recurrence were censored at their last date of follow-up. We tested non-inferiority at 2 years with the Kaplan-Meier estimator of the survival proportion with an absolute 10% margin, with Greenwood's variance estimator for the diff erence between two survival proportions. 22, 23 KaplanMeier survival curves (not restricted to 2 years) are presented with 95% CIs. Cox proportional hazard ratios (HRs) were calculated for the overall groups and for diff erent subgroups (stage and national trial offi ce). The CI of the HR was provided to show the precision of the estimate, not to assess non-inferiority. We assessed the assumption of proportional hazards by use of Schoenfeld residuals and by testing a time-dependent covariate, defi ned as the interaction between treatment group and log survival time. We did a test for interaction to explore heterogeneity in subgroups, and also calculated the number needed to treat based on survival probabilities and HR estimates. We calculated overall survival from the date 
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. All 583 patients were included in the intention-to-treat analysis. Baseline characteristics were similar between groups (table 1), but slightly more patients than predicted from the previous trial 3 had stage III tumours. 580 cases (99%) were submitted for central pathological review, 555 (96%) of which were confi rmed as intermediate-risk histology and 502 (87%) of which were confi rmed as stage II-III (table 2). The distribution of the few patients who were ineligible because of adverse tumour factors (stage IV and high-risk histology) after pathological review did not diff er signifi cantly. For patients who had details available of postoperative treatment of the high-risk tumours, nine of 14 had their postoperative treatment intensifi ed to take account of the review information.
Results
Between
Median follow-up was 60·8 months (IQR 40·8-79·8) for all randomly assigned patients. 39 events (including 36 relapses) occurred in the group without doxorubicin compared with 26 events (24 relapses) in the group with doxorubicin. The absolute diff erence in event-free survival at 2 years was 4·4% (95% CI 0·4-9·3), which did not surpass the predefi ned limit (table 3) . The 2 year estimates of event-free survival were 88·2% (95% CI 84·5-92·1) without doxorubicin versus 92·6% (89·6-95·7) with doxorubicin. 22 patients would need to receive doxorubicin to prevent one relapse (appendix).
We noted no signifi cant diff erences between the groups for 5 year event-free survival or 5 year overall survival (table 3, fi gure 2). The HR for any event was 1·55 (95% CI 0·94-2·54) and for death was 0·81 (0·35-1·89). Only three fi rst relapses happened after 5 years, all in the group receiving doxorubicin. 424 patients met the criteria for the per-protocol analysis. We noted a small increase in the size of the absolute diff erence in 2 year event-free survival in the per-protocol population (table 3) . The number needed to treat with doxorubicin to prevent one excess relapse remained at about 22 patients (fi gure 2).
When outcome was analysed separately by tumour stage, the diff erences in 2 year event-free survival (table 3) and corresponding increase in HR for any event were similar for stage II and stage III tumours. We also did Kaplan-Meier survival curve analyses for events over the entire time course (appendix).
17 (3%) patients had hepatic veno-occlusive disease, 11 during preoperative chemotherapy and eight during postoperative chemo therapy, with two patients having more than one episode of veno-occlusive disease. Four (<1%) children, all from Brazil, died after treatmentrelated toxic eff ects: three in fi rst remission (one from neutropenic sepsis who received treatment including doxorubicin, and one each from varicella and metabolic seizure, both of whom received treatment excluding
Treatment including doxorubicin
Treatment without doxorubicin
Diff erence (95% CI)
Intention-to-treat population (n=583) n=291 n=292 Most relapses (83%) occurred within 2 years of diagnosis in both treatment groups (table 4). 85% of stage III tumours received irradiation, with equal distribution between the two groups (appendix). Details of relapse therapy were reported in 41 of 60 cases. No child received further doxorubicin after assigned treatment with doxorubicin, whereas doxorubicin was given to 11 children relapsing after the assigned treatment with no doxorubicin.
Discussion
Our results show that omission of doxorubicin from the postoperative chemotherapy regimen of vincristine and actinomycin D for patients with stage II and stage III Wilms' tumours of intermediate-risk histological subtype was not signifi cantly worse in clinical terms than standard treatment with all three drugs, with only a small decrease in event-free survival (panel). 5 year overall survival was unaff ected by omission of doxorubicin, and remained high. Relapses with a site missing 2 (<1%) 3 (<1%)
Data are number of patients (%). *23 lung only, three liver only, two lung and liver, four lung and other extra-abdominal sites, and two extra-abdominal sites only.
Table 4: Sites of relapse in the intention-to-treat population
Risk stratifi cation that includes an individualised histological assessment of tumour response in vivo has allowed further optimisation of the overall burden of treatment for children with Wilms' tumours given preoperative chemotherapy followed by delayed nephrectomy, by reducing the proportion of patients for whom doxorubicin is indicated in their postoperative chemotherapy. The results of this trial have changed the practice of the SIOP Renal Tumours Study Group. However, patients with stage II-III Wilms' tumours of high-risk blastemal type should continue to be given doxorubicin.
Although doxorubicin has been included in standard chemotherapy regimens since the 1980s for patients with stage III Wilms' tumour, no conclusive evidence has shown that front-line doxorubicin treatment improves survival. 26 Two randomised trials begun in the 1980s (National Wilms Tumor Study Group 3 [NWTSG 3] and SIOP-6) 19, 25 tested the removal of doxorubicin from postnephrectomy chemotherapy for stage II and stage III Wilms' tumour. Randomisation in SIOP 6 was closed early because of an excess of relapses in the treatment groups without doxorubicin, but no diff erence in overall survival was found in the fi nal analysis of stage II cases with lymph node involvement and stage III cases. In NWTSG 3, 19 a numerical survival advantage for doxorubicin was noted only in patients with stage III disease who were randomly assigned to a reduced dose (10·8 Gy) of fl ank radiotherapy. In both studies, few patients were included in the doxorubicin groups and no diff erence in overall survival was detected after long-term follow-up.
The absence of superior outcomes in previous trials that were restricted in statistical power, and the increasing recognition of the late adverse eff ects associated with doxorubicin therapy, suggested that the role of doxorubicin in the management of some patients with localised, non-anaplastic Wilms' tumour should be reassessed. Our trial incorporated new information about the risk of relapse, according to histological response, into the initial risk-stratifi cation process. Although none of the survival endpoints reached signifi cance in this treatment-reduction setting, reliable quantifi cation of the potential risk of excess relapse from omission of a drug that might impair long-term quality of life and survival was important. We therefore did several per-protocol analyses to test the robustness of the results.
The most conservative included an analysis of patients whose eligibility of stage II-III, intermediate-risk histology Wilms' tumour was confi rmed by central pathological review, taking account of the treatment received. By maximising any potential treatment eff ect, these analyses helped to support the robustness of our fi ndings. The trial could not be adequately powered to analyse outcomes separately by tumour stage because of the few expected events, even in a large multinational trial. However, we did this analysis to explore any signs of a diff erential eff ect and showed that omission of doxorubicin was not signifi cantly worse in clinical terms-for patients with stage II or stage III intermediaterisk histology. Our data for stage II tumours are similar to a longer-term analysis of outcome of stage II tumours staged after immediate nephrectomy in the NWTSG 4 trial, 27 for which two-drug (vincristine plus actinomycin D) chemotherapy without doxorubicin was the standard after the NWTSG 3 trial. 19 This previous analysis focused on mechanical factors (tumour spill) to stratify stage II patients, whereas our study used in-vivo histological responses and would have placed tumours with spill into stage III. Encouragingly, our data suggest that stage III tumours can be treated eff ectively without doxorubicin, whereas the Children's Oncology Group recommend that tumours with spill should receive doxorubicin. 28 The applicability of our results is restricted to patients with Wilms' tumour given preoperative chemotherapy, which is standard clinical practice in most European and many other countries. Furthermore, the ultimate goal of showing avoidance of symptomatic cardiotoxicity needs more than 20 years of follow-up, which is in progress. However, the overall benefi t of doxorubicin in the long-term outcomes of children with Wilms' tumour has 14 This group might therefore be able to avoid doxorubicin without a higher relapse rate. A previous Cochrane review 24 that assessed treatment including anthracyclines versus treatment not including anthracyclines for childhood cancers identifi ed two randomised trials that have been done for Wilms' tumour. One of the trials (SIOP-6) 25 was excluded from the formal analysis because a 25% diff erence was noted between the study groups in cumulative dose of treatments other than anthracyclines. In the other study (National Wilms Tumor Study Group 3), 19 children were randomly assigned with a 2×2 factorial design that compared treatment with or without doxorubicin, and included random assignment to diff erent radiation doses of 10 or 20 Gy (K2 or DD2) in stage III, or 0 or 20 Gy in stage II Wilms' tumours, after immediate nephrectomy. None of the studies used histological assessment of the tumour as a stratifi cation technique.
Interpretation
To our knowledge, ours is the fi rst randomised study to test, in isolation, omission of doxorubicin from the postoperative treatment of stage II-III, intermediate-risk histology Wilms' tumour. Our results build on the long-term follow-up of the SIOP-6 and NWTSG 3 trials, add to the evidence base that doxorubicin is not necessary for optimum control of stage II or III Wilms' tumours without high-risk histological features after preoperative chemotherapy, and emphasise the need for further research into the molecular drivers of chemotherapy resistance in the blastemal component of Wilms' tumour.
also been questioned by investigators in North America, who use an immediate nephrectomy approach as standard. 29 Nonetheless, doxorubicin is still thought to contribute to eff ectiveness in some settings, including high-risk blastemal-type Wilms' tumour 30 and metastatic disease, even when the metastatic volume is low and detectable only by CT. 31 Anthracyclines cause dose-related cardiotoxicity, and cause an additive eff ect in left-sided stage III tumours in which fl ank irradiation might encompass part of the heart muscle. 10, 11 International follow-up guidelines suggest that survivors who receive at least 250 mg/m² of doxorubicin-the dose given in our three-drug regimen-need continual cardiac surveillance. Hence, omission of doxorubicin could remove a perpetual reminder of possible ill health as a result of treatment for Wilms' tumour survivors who are otherwise healthy.
Because of the complexity of the histological composition of Wilms' tumours, the personalised response of each tumour was not based only on the percentage of necrosis after preoperative chemotherapy, but also on the predominant cell type in the residual viable component. 13, 30 When the percentage of viable tumour consists of more than two-thirds primitive blastemal cells, in the setting of less than two-thirds necrosis, the tumour is classifi ed as high-risk blastemaltype Wilms' tumour. These patients were excluded from random assignment and continued to receive doxorubicin. However, this histological classifi cation is subjective and the accuracy of risk stratifi cation needs to be improved; a quantitative assessment of the total volume of residual blastema after preoperative chemotherapy might achieve such accuracy. Preliminary analyses suggest residual blastema might be an adverse prognostic factor in this solid tumour, akin to measuring low residual disease in childhood leukaemia. 30 Alternative avenues of research are characterisation of molecular biomarkers associated with chemotherapy-resistant blastema, with whole-exome sequencing and other assessments in progress. 32 Our results show that incorporation of a measure of the in-vivo chemosensitivity of each child's tumour into risk stratifi cation has allowed further reduction of treatment intensity for children with localised, stage II or III Wilms' tumour in a controlled way. Although the small excess of relapses in the reduced treatment arm did not lead to a rise in the number of deaths even in the long term, a few additional children might need treatment for relapse. More accurate prognostic risk predictors are needed, and the identifi cation of novel molecular, histological, and clinical 33 risk factors is a priority to allow further stratifi cation of treatment intensity.
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